Each Wegovy pen contains four doses, lasting four weeks. The pens are colour-coded by dose — you'll receive a new pen when your dose increases. 

The exception is the newer 7.2mg dose, which comes as individual single-dose pens (one per injection).[3] For all standard doses (0.25mg through to 2.4mg), one pen = four weekly injections. 

Wegovy uses a 16-week dose escalation schedule: 0.25mg (weeks 1–4), 0.5mg (weeks 5–8), 1mg (weeks 9–12), 1.7mg (weeks 13–16), then 2.4mg as the maintenance dose from week 17.

If you experience significant side effects at any point, your clinician may pause the escalation schedule. All dose changes are guided by your Bliss clinician. 

Wegovy and Ozempic contain the same active ingredient — semaglutide — but are different medicines. Wegovy is licensed in the UK specifically for chronic weight management. Ozempic is licensed for type 2 diabetes management and uses a lower dose. Ozempic is not licensed or prescribed by Bliss for weight loss. Wegovy is the correct, MHRA-approved semaglutide product for weight management.

No — Wegovy and Mounjaro are different medications. Wegovy contains semaglutide (a GLP-1 receptor agonist); Mounjaro contains tirzepatide (a dual GLP-1 and GIP receptor agonist). Mounjaro has produced higher average weight loss in clinical trials (20.9% vs 14.9%), attributed to its dual receptor mechanism. Both are available at Bliss. Your clinician will recommend the most appropriate treatment for you.

Both are effective, clinically proven weight loss injections. In clinical trials, Mounjaro produced greater average weight loss (20.9% vs Wegovy's 14.9%), attributed to its additional GIP receptor mechanism.  

However, individual responses vary considerably — some patients achieve excellent results on Wegovy and some prefer its established, longer evidence base. 

 
Your Bliss clinician will recommend the most appropriate treatment based on your individual profile. Both are available at Bliss. 

Yes — Wegovy has a robust clinical evidence base across multiple large-scale randomised controlled trials. In the STEP 1 trial, semaglutide 2.4mg produced average weight loss of 14.9% over 68 weeks — significantly more than placebo. Results are greatest when combined with dietary changes and regular physical activity.  

Individual outcomes vary, but the evidence consistently shows Wegovy produces clinically meaningful weight loss. 

Wegovy is MHRA-licensed for weight management in the UK and has been prescribed to millions of patients worldwide. It is safe when prescribed following a clinical assessment by a registered prescriber.  

At Bliss, all prescriptions are issued after a full online consultation confirming eligibility and reviewing contraindications. As a GPhC-registered pharmacy, Bliss dispenses only genuine, manufacturer-supplied Wegovy through regulated UK supply chains. 

Clinical data shows that weight typically returns after stopping Wegovy, as the appetite-regulating effects of semaglutide are not permanent. Bliss treats Wegovy as part of a longer-term programme — including dietary support and clinician oversight — rather than a standalone prescription.  

When you are ready to stop, your clinician will guide a planned approach and help you maintain results through lifestyle and nutritional strategies. 

Alcohol is not strictly contraindicated with Wegovy, but it can worsen nausea — one of the most common side effects — and adds calories that can slow your progress. If you are also taking diabetes medication, alcohol may lower blood sugar. Moderation is sensible. Speak to your Bliss clinician if you have specific concerns.